Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
Hosted on MSN8h
William Blair Initiates Coverage of Altimmune (ALT) with Market Perform RecommendationFintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...
Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...
EST Altimmune (ALT) files $400M mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...
GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...
Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 20% growth forecast for the ...
As of 3:32:45 PM EST. Market Open. GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company ...
Altimmune, Inc. announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso, who bring extensive experience in the biopharmaceutical industry.
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research ...
Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback